Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNYNF) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sanofi (SNYNF) over the last 12 years, with Q4 2025 value amounting to -$409.8 million.

  • Sanofi's Gains from Investment Securities fell 477.48% to -$409.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.4 billion, marking a year-over-year decrease of 2207.68%. This contributed to the annual value of -$117.5 million for FY2025, which is 7033.07% up from last year.
  • According to the latest figures from Q4 2025, Sanofi's Gains from Investment Securities is -$409.8 million, which was down 477.48% from -$391.1 million recorded in Q4 2024.
  • In the past 5 years, Sanofi's Gains from Investment Securities ranged from a high of -$391.1 million in Q4 2024 and a low of -$409.8 million during Q4 2025
  • Over the past 3 years, Sanofi's median Gains from Investment Securities value was -$391.6 million (recorded in 2023), while the average stood at -$397.5 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first rose by 13.69% in 2024, then crashed by 477.48% in 2025.
  • Sanofi's Gains from Investment Securities (Quarter) stood at -$391.6 million in 2023, then grew by 0.14% to -$391.1 million in 2024, then decreased by 4.77% to -$409.8 million in 2025.
  • Its last three reported values are -$409.8 million in Q4 2025, -$391.1 million for Q4 2024, and -$391.6 million during Q4 2023.